APP and Alzheimer disease: The chronic administration of the TfRMAb-TNFR fusion protein to double transgenic AD mice caused a reduction in Abeta amyloid plaque, a reduction in markers of neuroinflammation, and improved recognition memory (Chang R. et al., 2017).